Chronic morphine's role on innate immunity, bacterial susceptibility and implications in wound healing

Josephine Martin, Sabita Roy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Opioids are considered the gold standard in treating pain. Patients who are prescribed morphine for the management of chronic pain also present themselves with complications such as increased susceptibility to opportunistic infections and inadequate healing of wounds. Yet, an in vivo model useful in elucidating mechanisms' underlying this phenomenon has not been established. Through the standardization of an in vivo wound murine model, our laboratory has characterized the suppressive effects of morphine on wound healing events in the presence of an infection. Our model is the first to mimic the clinical manifestations of bacterial or viral infection seen in opioid user and abuser populations. Our findings show a marked decrease in wound closure and integrity following chronic morphine administration in the presence of LPS or the HIV-1 protein Tat. With respect to the bacterial infection model, a delay in neutrophil infiltration/decrease in macrophage infiltration into the wound beds was also seen. Interestingly, the macrophage chemoattractant MCP-1 levels were significantly decreased following chronic morphine treatment whereas no modulation was seen for the neutrophil chemoattractant MIP-2. Neutrophil chemotaxis towards a chemical gradient showed morphine's suppressive effects occurring directly on the immune cell, as well as, on the expression of chemoattractant factors independent of MIP-2. In our HIV-1 Tat model, our data implicates an immune suppression in wound healing events following HIV-1 protein Tat and chronic morphine co-treatment and shows the potentially detrimental effects chronic morphine administration may have in the wound healing processes of HIV positive patients. Taken together, these findings indicate that the mechanism by which morphine exerts its immunosuppressive effects on pro-inflammatory responses varies depending on the immune cell type and depending on the type of infectious agent present. Morphine's suppression of early stage innate immunity, critical in determining the outcome of pathogen resolution in wounds, shifts the outcome to a persistence of pathogen onboard, prolonged inflammation, pathogen dissemination and inadequate wound healing.

Original languageEnglish (US)
Title of host publicationChemokine Receptors and NeuroAIDS
Subtitle of host publicationBeyond Co-Receptor Function and Links to Other Neuropathologies
PublisherSpringer New York
Pages337-352
Number of pages16
ISBN (Electronic)9781441907936
ISBN (Print)9781441907929
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Innate Immunity
Wound Healing
Morphine
Chemotactic Factors
Human Immunodeficiency Virus Proteins
HIV-1
Wounds and Injuries
Bacterial Infections
Opioid Analgesics
Neutrophils
Macrophages
Neutrophil Infiltration
Opportunistic Infections
Virus Diseases
Chemotaxis
Immunosuppressive Agents
Chronic Pain
HIV
Inflammation
Pain

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Martin, J., & Roy, S. (2010). Chronic morphine's role on innate immunity, bacterial susceptibility and implications in wound healing. In Chemokine Receptors and NeuroAIDS: Beyond Co-Receptor Function and Links to Other Neuropathologies (pp. 337-352). Springer New York. https://doi.org/10.1007/978-1-4419-0793-6_15

Chronic morphine's role on innate immunity, bacterial susceptibility and implications in wound healing. / Martin, Josephine; Roy, Sabita.

Chemokine Receptors and NeuroAIDS: Beyond Co-Receptor Function and Links to Other Neuropathologies. Springer New York, 2010. p. 337-352.

Research output: Chapter in Book/Report/Conference proceedingChapter

Martin, J & Roy, S 2010, Chronic morphine's role on innate immunity, bacterial susceptibility and implications in wound healing. in Chemokine Receptors and NeuroAIDS: Beyond Co-Receptor Function and Links to Other Neuropathologies. Springer New York, pp. 337-352. https://doi.org/10.1007/978-1-4419-0793-6_15
Martin J, Roy S. Chronic morphine's role on innate immunity, bacterial susceptibility and implications in wound healing. In Chemokine Receptors and NeuroAIDS: Beyond Co-Receptor Function and Links to Other Neuropathologies. Springer New York. 2010. p. 337-352 https://doi.org/10.1007/978-1-4419-0793-6_15
Martin, Josephine ; Roy, Sabita. / Chronic morphine's role on innate immunity, bacterial susceptibility and implications in wound healing. Chemokine Receptors and NeuroAIDS: Beyond Co-Receptor Function and Links to Other Neuropathologies. Springer New York, 2010. pp. 337-352
@inbook{7d2dd47a5696462f994d9b02cca3a4c8,
title = "Chronic morphine's role on innate immunity, bacterial susceptibility and implications in wound healing",
abstract = "Opioids are considered the gold standard in treating pain. Patients who are prescribed morphine for the management of chronic pain also present themselves with complications such as increased susceptibility to opportunistic infections and inadequate healing of wounds. Yet, an in vivo model useful in elucidating mechanisms' underlying this phenomenon has not been established. Through the standardization of an in vivo wound murine model, our laboratory has characterized the suppressive effects of morphine on wound healing events in the presence of an infection. Our model is the first to mimic the clinical manifestations of bacterial or viral infection seen in opioid user and abuser populations. Our findings show a marked decrease in wound closure and integrity following chronic morphine administration in the presence of LPS or the HIV-1 protein Tat. With respect to the bacterial infection model, a delay in neutrophil infiltration/decrease in macrophage infiltration into the wound beds was also seen. Interestingly, the macrophage chemoattractant MCP-1 levels were significantly decreased following chronic morphine treatment whereas no modulation was seen for the neutrophil chemoattractant MIP-2. Neutrophil chemotaxis towards a chemical gradient showed morphine's suppressive effects occurring directly on the immune cell, as well as, on the expression of chemoattractant factors independent of MIP-2. In our HIV-1 Tat model, our data implicates an immune suppression in wound healing events following HIV-1 protein Tat and chronic morphine co-treatment and shows the potentially detrimental effects chronic morphine administration may have in the wound healing processes of HIV positive patients. Taken together, these findings indicate that the mechanism by which morphine exerts its immunosuppressive effects on pro-inflammatory responses varies depending on the immune cell type and depending on the type of infectious agent present. Morphine's suppression of early stage innate immunity, critical in determining the outcome of pathogen resolution in wounds, shifts the outcome to a persistence of pathogen onboard, prolonged inflammation, pathogen dissemination and inadequate wound healing.",
author = "Josephine Martin and Sabita Roy",
year = "2010",
month = "1",
day = "1",
doi = "10.1007/978-1-4419-0793-6_15",
language = "English (US)",
isbn = "9781441907929",
pages = "337--352",
booktitle = "Chemokine Receptors and NeuroAIDS",
publisher = "Springer New York",

}

TY - CHAP

T1 - Chronic morphine's role on innate immunity, bacterial susceptibility and implications in wound healing

AU - Martin, Josephine

AU - Roy, Sabita

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Opioids are considered the gold standard in treating pain. Patients who are prescribed morphine for the management of chronic pain also present themselves with complications such as increased susceptibility to opportunistic infections and inadequate healing of wounds. Yet, an in vivo model useful in elucidating mechanisms' underlying this phenomenon has not been established. Through the standardization of an in vivo wound murine model, our laboratory has characterized the suppressive effects of morphine on wound healing events in the presence of an infection. Our model is the first to mimic the clinical manifestations of bacterial or viral infection seen in opioid user and abuser populations. Our findings show a marked decrease in wound closure and integrity following chronic morphine administration in the presence of LPS or the HIV-1 protein Tat. With respect to the bacterial infection model, a delay in neutrophil infiltration/decrease in macrophage infiltration into the wound beds was also seen. Interestingly, the macrophage chemoattractant MCP-1 levels were significantly decreased following chronic morphine treatment whereas no modulation was seen for the neutrophil chemoattractant MIP-2. Neutrophil chemotaxis towards a chemical gradient showed morphine's suppressive effects occurring directly on the immune cell, as well as, on the expression of chemoattractant factors independent of MIP-2. In our HIV-1 Tat model, our data implicates an immune suppression in wound healing events following HIV-1 protein Tat and chronic morphine co-treatment and shows the potentially detrimental effects chronic morphine administration may have in the wound healing processes of HIV positive patients. Taken together, these findings indicate that the mechanism by which morphine exerts its immunosuppressive effects on pro-inflammatory responses varies depending on the immune cell type and depending on the type of infectious agent present. Morphine's suppression of early stage innate immunity, critical in determining the outcome of pathogen resolution in wounds, shifts the outcome to a persistence of pathogen onboard, prolonged inflammation, pathogen dissemination and inadequate wound healing.

AB - Opioids are considered the gold standard in treating pain. Patients who are prescribed morphine for the management of chronic pain also present themselves with complications such as increased susceptibility to opportunistic infections and inadequate healing of wounds. Yet, an in vivo model useful in elucidating mechanisms' underlying this phenomenon has not been established. Through the standardization of an in vivo wound murine model, our laboratory has characterized the suppressive effects of morphine on wound healing events in the presence of an infection. Our model is the first to mimic the clinical manifestations of bacterial or viral infection seen in opioid user and abuser populations. Our findings show a marked decrease in wound closure and integrity following chronic morphine administration in the presence of LPS or the HIV-1 protein Tat. With respect to the bacterial infection model, a delay in neutrophil infiltration/decrease in macrophage infiltration into the wound beds was also seen. Interestingly, the macrophage chemoattractant MCP-1 levels were significantly decreased following chronic morphine treatment whereas no modulation was seen for the neutrophil chemoattractant MIP-2. Neutrophil chemotaxis towards a chemical gradient showed morphine's suppressive effects occurring directly on the immune cell, as well as, on the expression of chemoattractant factors independent of MIP-2. In our HIV-1 Tat model, our data implicates an immune suppression in wound healing events following HIV-1 protein Tat and chronic morphine co-treatment and shows the potentially detrimental effects chronic morphine administration may have in the wound healing processes of HIV positive patients. Taken together, these findings indicate that the mechanism by which morphine exerts its immunosuppressive effects on pro-inflammatory responses varies depending on the immune cell type and depending on the type of infectious agent present. Morphine's suppression of early stage innate immunity, critical in determining the outcome of pathogen resolution in wounds, shifts the outcome to a persistence of pathogen onboard, prolonged inflammation, pathogen dissemination and inadequate wound healing.

UR - http://www.scopus.com/inward/record.url?scp=84920013149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920013149&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-0793-6_15

DO - 10.1007/978-1-4419-0793-6_15

M3 - Chapter

AN - SCOPUS:84920013149

SN - 9781441907929

SP - 337

EP - 352

BT - Chemokine Receptors and NeuroAIDS

PB - Springer New York

ER -